2021
319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial
KAHL S, OFSTAD A, ZINMAN B, WANNER C, SCHUELER E, INZUCCHI S, RODEN M. 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial. Diabetes 2021, 70 DOI: 10.2337/db21-319-or.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseNAFLD fibrosis scoreCardiorenal outcomesFibrosis riskEMPA-REG OUTCOMELiver fat contentRisk of steatosisEffect of empagliflozinFatty liver diseaseType 2 diabetesCause deathDaily empagliflozinSteatosis indexHeart failureFibrosis scoreLiver diseaseCox regressionCardiovascular diseaseHigh riskEmpagliflozinPlaceboSteatosisRisk categoriesBaselineMeasures analysisEffect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial
Hamilton A, Fitchett D, Zinman B, Inzucchi S, Wanner C, Anker S, Pocock S, Kaspers S, Mattheus M, Vedin O, Hantel S, Lund S. Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial. Heart Lung And Circulation 2021, 30: s220-s221. DOI: 10.1016/j.hlc.2021.06.278.Peer-Reviewed Original ResearchEffect of empagliflozinEMPA-REGMyocardial infarctionTotal eventsInfarctionEmpagliflozinSubtypesTrials
2020
131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome
INZUCCHI S, ZINMAN B, WANNER C, FITCHETT D, ANKER S, POCOCK S, KASPERS S, GEORGE J, JOHANSEN O, JAMAL W, HANTEL S, LUND S. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes 2020, 69 DOI: 10.2337/db20-131-lb.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseEMPA-REG OUTCOMEEffect of empagliflozinTotal burdenEli LillyHeart failure riskType 2 diabetesNervous system disordersTotal eventsAdvisory PanelSt. Jude MedicalLowest NNTMundipharma InternationalSanofi GenzymeCause hospitalizationCause mortalityCardiovascular mortalityFrequent hospitalizationsDohme Corp.Novo Nordisk A/SCardiovascular diseaseCardiac dimensionsHospitalization categoriesSystem disordersEmpagliflozin
2019
P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease
McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, Von Eynatten M, Johansen O, Elsasser U, Pocock S, Fitchett D, Jamal W, Hantel S, Lund S. P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease. European Heart Journal 2019, 40: ehz746.0869. DOI: 10.1093/eurheartj/ehz746.0869.Peer-Reviewed Original ResearchEMPA-REG OUTCOME trialEffect of empagliflozinCause hospitalisationType 2 diabetesHospitalisation eventsOutcome trialsHeart failureCardiovascular diseaseMajor adverse CV eventsTotal burdenAdjusted hazard ratioAdverse CV eventsAtherosclerotic cardiovascular diseaseCox regression modelStandard of careEvent rate ratioCV deathCV eventsEmpagliflozin groupPlacebo patientsRecurrent hospitalisationsCV diseasePlacebo groupFirst eventHazard ratio248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial
INZUCCHI S, ZINMAN B, GEORGE J, MATTHEUS M, EYNATTEN M, WANNER C, HAUSKE S. 248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial. Diabetes 2019, 68 DOI: 10.2337/db19-248-or.Peer-Reviewed Original ResearchNon-proteinuric chronic kidney diseaseEffect of empagliflozinChronic kidney diseaseCardiorenal outcomesBoehringer Ingelheim PharmaceuticalsEMPA-REGCV deathKidney diseaseJanssen PharmaceuticalsEli LillyAdverse cardiorenal outcomesComposite kidney outcomeLower proteinuria levelsPrior CV diseaseSubgroup of patientsStrong risk predictorType 2 diabetesAdvisory PanelCKD populationKidney outcomesOvert albuminuriaOvert proteinuriaCause mortalityCV diseaseLower eGFR
2018
Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline
FITCHETT D, SCIRICA B, INZUCCHI S, CANNON C, MCGUIRE D, JOHANSEN O, SAMBEVSKI S, HEHNKE U, GEORGE J, ZINMAN B. Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline. Diabetes 2018, 67 DOI: 10.2337/db18-1123-p.Peer-Reviewed Original ResearchEMPA-REG OUTCOME trialBoehringer Ingelheim PharmaceuticalsBaseline CV riskCV deathProportion of patientsCause deathEisai Inc.CV riskOutcome trialsRisk scoreJanssen PharmaceuticalsGlaxoSmithKline plcBristol-Myers Squibb CompanyNovo Nordisk A/SLexicon PharmaceuticalsEli LillyBenefits of empagliflozinBoehringer Ingelheim GmbHResidual CV riskEffect of empagliflozinTIMI risk scorePfizer Inc.Sanofi-AventisCardiovascular risk scoreAmgen Inc.
2016
EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK
Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK. Canadian Journal Of Cardiology 2016, 32: s122-s123. DOI: 10.1016/j.cjca.2016.07.182.Peer-Reviewed Original Research10 Effect of Empagliflozin on Mortality and Causes of Death in Patients with Type 2 Diabetes at High Cardiovascular Risk
Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. 10 Effect of Empagliflozin on Mortality and Causes of Death in Patients with Type 2 Diabetes at High Cardiovascular Risk. Canadian Journal Of Diabetes 2016, 40: s4-s5. DOI: 10.1016/j.jcjd.2016.08.013.Peer-Reviewed Original ResearchEFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL
Fitchett D, Zinman B, Lachin J, Mattheus M, George J, Johansen O, Inzucchi S. EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2016, 32: s90-s91. DOI: 10.1016/j.cjca.2016.07.124.Peer-Reviewed Original ResearchLBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE
Lee D, Monteiro P, Clark D, Hantel S, Woerle H, Inzucchi S, Fitchett D. LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE. Journal Of Hypertension 2016, 34: e520. DOI: 10.1097/01.hjh.0000501423.64635.bd.Peer-Reviewed Original ResearchHeart failure hospitalizationHigh cardiovascular riskCardiovascular deathFailure hospitalizationHeart failureStandard of careType 2 diabetesEmpagliflozin groupCardiovascular riskMajor adverse cardiovascular eventsEMPA-REG OUTCOME trialEMPA-REG OUTCOMEAdverse cardiovascular eventsEffect of empagliflozinHeart failure outcomesMedian observation timeRisk of hospitalizationCardiovascular eventsPlacebo groupAdverse eventsEffect of ageOutcome trialsSafety profileMean ageBaseline age